Drug intelligence / Profile preview

NBA-1603

Development stage: Preclinical
Lead developer: NB Health Laboratory
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

NBA-1603 is a monoclonal antibody drug candidate that acts as an antagonist of the prostanoid EP4 receptor. It is being developed by NB Health Laboratory for potential use in immune system diseases, infectious diseases, and skin and musculoskeletal diseases. The primary indication currently under investigation is ankylosing spondylitis. As of the latest update, NBA-1603 remains in preclinical development and has not yet entered clinical trials or received regulatory approval[1][2][3].

Targets

PTGER4 (Prostaglandin E2 receptor EP4 subtype)

Beyond the preview

Go deeper on NBA-1603.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NBA-1603.

Explore the full profile